Expanding Global Reach VIVUS has recently entered new markets such as Korea and Kuwait, demonstrating their commitment to expanding their global footprint and increasing their patient access. This presents opportunities to offer localized distribution, marketing services, and partnership support for further market penetration.

Innovative Telehealth Initiatives With their recent collaboration with UpScriptHealth to provide telehealth services through the 'Engage' program, VIVUS is enhancing patient engagement and access to treatment. This opens avenues for sales of telehealth platforms, remote monitoring tools, and patient management solutions.

Focus on Obesity and Binge Eating VIVUS has developed and marketed Qsymia for obesity and binge eating disorder, showcasing a strong product portfolio in metabolic and behavioral health. There are opportunities to offer complementary therapies, nutritional support, and digital health tools tailored to these patient groups.

Clinical Development and Efficacy Data VIVUS emphasizes research and real-world data to demonstrate the safety and efficacy of its products, which can be leveraged to promote evidence-based sales approaches, clinical partnerships, and physician education programs to drive adoption.

Financial Position and Growth Potential With revenues between $100M and $250M and recent product launches, VIVUS is positioned for growth in the pharmaceutical and metabolic markets. This indicates potential opportunities for investment in sales channels, promotional campaigns, and strategic partnerships to accelerate market share expansion.